

# Patterns of Radiotherapy Practice in the Management of Gastric Cancer: Preliminary Findings from the Quality Research in Radiation Oncology (QRRO) GI Committee Process Surveys

*Karyn A. Goodman, M.D.<sup>1</sup>; Najma Khalid, M.S.<sup>2</sup>; Lisa A. Kachnic, M.D.<sup>3</sup>; Bruce D. Minsky, M.D.<sup>4</sup>; Cheryl L. Crozier, R.N.<sup>2</sup>; Jean B. Owen, Ph.D.<sup>2</sup>;  
 J. Frank Wilson, M.D.<sup>5</sup>; Charles R. Thomas, Jr., M.D.<sup>6</sup>*

<sup>1</sup>Memorial Sloan-Kettering Cancer Center, New York, NY; <sup>2</sup>American College of Radiology, Philadelphia, PA; <sup>3</sup>Massachusetts General Hospital Cancer Center, Boston, MA; <sup>4</sup>University of Chicago, Chicago, IL; <sup>5</sup>Medical College of Wisconsin, Milwaukee, WI; <sup>6</sup>Knight Cancer Institute, Oregon Health and Science University, Portland, OR

## Purpose/Objectives

- American College of Radiology, Quality Research in Radiation Oncology (QRRO), formerly Patterns of Care (PCS), aims to provide an evidence base for quality of care in radiotherapy (RT).
- Through process surveys, QRRO aims to:
  - Conduct surveys allowing documentation of process of care and quality assurance
  - Collect data
  - Define a core set of process measures for major cancers
  - Document the effects of clinical trials results, practice guidelines and appropriateness criteria
  - Identify factors associated with higher compliance with clinical standards
  - Describe patient and practice-based parameters
  - Benchmark and track the distribution and utilization of advanced radiotherapy technology
  - Disseminate information and educate target audiences
- Gastric cancer was selected as one of 5 disease sites for study to determine the national patterns of radiotherapy practice in patients treated for Stage IB-IV (non-metastatic) gastric cancer

## Study Design

### National Process Survey

- A National Process Survey was developed for gastric cancer to measure:
  - Patient demographics
  - Geographic region
  - Practice setting
  - Insurance status
  - Workup and Studies
  - Medical History and Comorbidities
  - Staging and Extent of Disease
  - Treatment Course (Surgery, Radiotherapy, and Chemotherapy details)
- Two-stage stratified random sample of:
  - 106 Radiation oncology facilities nationwide invited (first stage)
  - Eligible cases within those facilities (second stage)
- Facility Survey Data & Process Survey Data used to calculate national averages and make statistically valid inferences for national process measures
- Survey data collected via retrospective review of patient charts and records
- Time period
  - 2005 - 2007

## Study Design

### Clinical Performance Measures

- The QRRO Gastrointestinal Cancers Committee defined a set of core clinical process measures (CPM) based on national practice guidelines which can be used to measure performance:
  - Use of CT-based simulation and treatment planning
  - Use of dose volume histograms (DVH) to evaluate normal tissue doses to the kidneys and liver
  - Completion of planned RT course within the prescribed time frame
- Emerging clinical process measures were defined based on best available evidence and expert consensus:
  - Use of Intensity Modulated Radiotherapy (IMRT) treatment delivery when 3D conformal technology is used in treatment planning
  - Use of image-guided tools (IGRT), other than computed tomography scans, for radiation therapy target delineation
  - Use of preoperative (neoadjuvant) RT

## Computation of CPMs

Proportion of patients that meet the CPM

=

Sub-set of the patient population with the condition that meets the defined criteria

/

Patient population with the condition

Less

Patients with exclusions

## Results

### Demographics


- A total of 250 eligible pts treated for gastric cancer from 45 institutions were reviewed
- Six facilities had no eligible patients.
- Stratum-specific weighted percentages were calculated to reflect the distribution in the population as a whole
  - Median age was 62 years
  - 65% male
  - 68% Caucasian; 17% African American; 6% Asian; 8% other/unknown
  - AJCC 2002 pathologic stage was :13% stage I, 27% II, 30% IIIA, 9% IIIB, and 14% IV
  - Most pts (36%) were treated at small non-academic centers with the remainder split between large (24%) and medium (29%) non-academic facilities. Only 11% were treated at academic centers
  - 39% of pts were covered by Medicare, 29% had private insurance and 13% were covered by an HMO; only 4% had Medicaid as a payor

## Results


### Clinical Performance Measures

- CPMs were computed on data for 250 eligible patients at 45 institutions.

### Core CPM's



### Emerging CPM's



- IGRT techniques included: PET (n=20), MRI (n=1), respiratory gating and/or 4D-CT (n=22) and on-board imaging (n=10)

## Conclusions

- QRRO's analysis of radiation practice patterns for non-metastatic gastric cancer indicate widespread adoption of CT-based planning with the use of DVHs to evaluate normal tissue doses
- Most pts completed adjuvant RT in the prescribed time frame
- Emerging RT techniques such as IMRT and IGRT were not routinely incorporated into clinical practice during the evaluated time period
- These data will serve as a benchmark for future QRRO gastric cancer surveys